2 showed high affinity with Ki = 0.97 ( 0.48 nM for
VMAT2 in rat brains, whereas the (ꢀ)-enantiomer was
much less effective with Ki = 2.2 ( 0.3 μM.7 Furthermore,
radioactive (þ)-DTBZ was specifically distributed in re-
gions of the striatum in mice. These results indicated that
the binding of TBZ as well as that of DTBZ to VMAT2 is
stereospecific.
Due to the pharmaceutical significance of TBZ and
DTBZ, several reports8 have been published to date
including two recent excellent syntheses achieved by
Jonhson and Suh.9 As depicted in Scheme 1, these syn-
theses involved initial asymmetric installation at the C-1
position of the dihydroisoquinoline 3. The enantiomeri-
cally enriched 5 and 7 were then subjected to crucial
cyclization reactions, such as an intramolecular conjugate
addition and an aza-Claisen rearrangement/transannula-
tion, to produce tetrabenazine (1) effectively.
oxidative cyclizations is challenging because termination
of Prins cyclization by allylsilane has not been studied
intensively.11 The amino allylsilane 8 could arise from the
allylsilane 10, prepared by radical conjugate addition12
to R-hydroxymethyl acrylate 1113 and a Peterson type
olefination.14
Herein, we report the total synthesis of the tetrabenazine
alkaloids through an intramolecular aza-Prins-type cycli-
zation of an amino allylsilane using an oxidative CꢀH
activation.15
Scheme 2. Retrosynthetic Analysis
Scheme 1. Reported Syntheses of TBZ
To examine the viability of our cyclization strategy, we
first optimized the reaction conditions using the simple
amino allylsilane 13 as the substrate. The allylsilane 13 was
prepared from 3-(trimethylsilylmethyl)-but-3-en-1-ol16 by
tosylation and subsequent N-alkylation with tetrahydro-
isoquinoline (Scheme 3). Although several reports have
highlighted metal catalyzed CꢀH activation in benzylic or
allylic amine systems,17 we chose organic oxidizing agents
such as phenyliodine diacetate (PIDA), phenyliodine bis-
(trifluoroacetate) (PIFA), and dichlorodicyanoquinone
(DDQ) since they are stable solids that permit more prac-
tical as well as mild reaction conditions.18 To our delight,
treatment of the substrate 13 with PIDA in CH3CN at
Retrosynthetically, we envisioned the piperidinone ring
of TBZ being formed by an aza-Prins-type cyclization of
the amino allylsilane 8 followed by oxidative cleavage of
exomethylene (Scheme 2). We postulated that direct CꢀH
activation of the tetrahydroisoquinoline derivative 8 by a
single-electron oxidative agent would lead to an iminium
intermediate, which would undergo Prins-type cyclization
to give a benzo[a]quinolizidine ring system.10 In this trans-
formation, we expected a 2,5-trans piperidine would be
formed via the more favorable chairlike transition state
(TS) in which the isobutyl substituent is in an equatorial
position. On the other hand, the use of allylsilanes in
(12) Sibi, M. P.; Patil, K. Org. Lett. 2005, 7, 1453.
(13) Yu, C.; Liu, B.; Hu, L. J. Org. Chem. 2001, 66, 5413.
(14) Bunnelle, W. H.; Narayanan, B. A. Org. Synth. 1990, 69, 89.
(15) For syntheses of oxacycles via Prins cyclization using organic
oxidants, see: (a) Tu, W.; Liu, L.; Floreancig, P. E. Angew. Chem., Int.
Ed. 2008, 47, 4184. (b) Tu, W.; Floreancig, P. E. Angew. Chem., Int. Ed.
2009, 48, 4567. (c) Yu, B.; Jiang, T.; Li, J.; Su, Y.; Pan, X.; She, X. Org.
Lett. 2009, 11, 3442.
(16) Hydroxy allylsilane 12 was prepared by silylation of the dianion
of 3-methyl-3-buten-1-ol followed by desilylation of the silyl ether. For a
detailed procedure, see: Trost, B. M.; Chan, D. M. T.; Nanninga, N.
Org. Synth. 1984, 62, 58.
(17) (a) Li, C.-J.; Li, Z. J. Am. Chem. Soc. 2005, 127, 3672. (b) Li, Z.;
Bohle, D. S.; Li, C.-J. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8928.
(c) Li, C.-J. Acc. Chem. Res. 2009, 42, 335. (d)Murahashi, S.-I.; Nakae, T.;
Terai, H.; Komiya, N. J. Am. Chem. Soc. 2008, 130, 11005. (e) Catino, A.;
Nichols, J. M.; Nettles, B. J.; Doyle, M. P. J. Am. Chem. Soc. 2006, 128,
5648.
(18) For examples of activation of CꢀH bonds adjacent to nitrogen
using PIDA, PIFA, or DDQ, see: (a) Shu, X.-Z.; Xia, X.-F.; Yang,
Y.-F.; Ji, K.-G.; Liu, X.-Y.; Liang, Y.-M. J. Org. Chem. 2009, 74, 7464.
(b) Tsang, A. S.-K.; Todd, M. H. Tetrahedron Lett. 2009, 50, 1199.
(7) Kilbourn, M. R.;Lee, L.;VanderBorght, T.;Jewett, D. M.;Frey, K.
Eur. J. Pharmacol. 1995, 278, 249.
(8) (a) Yu, Q.; Luo, W.; Deschamps, J.; Holloway, H. W.; Kopajtic,
T.; Katz, J. L.; Brossi, A.; Greig, N. H. ACS Med. Chem. Lett. 2010, 1,
105. (b) Boldt, K. G.; Biggers, M. S.; Phifer, S. S.; Brine, G. A.; Rehder,
K. S. Synth. Commun. 2009, 39, 3574. (c) Kilbourn, M. R.; Lee, L. C.;
Heeg, M. J.; Jewett, D. M. Chirality 1997, 9, 59.
(9) (a) Rishel, M. J.; Amarasinghe, K. K. D.; Dinn, S. R.; Johnson,
B. F. J. Org. Chem. 2009, 74, 4001. (b) Paek, S.-M.; Kim, N.-J.; Shin, D.;
Jung, J.-K.; Jung, J.-W.; Chang, D.-J.; Moon, H.; Suh, Y.-G. Chem.;
Eur. J. 2010, 16, 4623.
(10) For iminium cyclization reactions using SET-photosensitiztion
or CAN, see: (a) Zhang, X.; Jung, Y. S.; Mariano, P. S.; Fox, M. A.;
Martin, P. S.; Merkert, J. Tetrahedron Lett. 1993, 34, 5239. (b) Yoon,
U. C.; Kim, K. T.; Oh, S. W.; Cho, D. W.; Mariano, P. S. Bull. Korean
Chem. Soc. 2001, 22, 1267.
(11) (a) Ghosh, A. K.; Cheng, X. Org. Lett. 2011, 13, 4108. (b)
Brizgys, G. J.; Jung, H. H.; Floreancig, P. E. Chem. Sci., DOI: 10.1039/
c1sc00670c.
Org. Lett., Vol. 13, No. 24, 2011
6501